Bioxcel therapeutics reports second quarter 2021 financial results and recent operational highlights

Phase 3 study of bxcl501 for the acute treatment of agitation associated with dementia expected to begin in q4 2021
BTAI Ratings Summary
BTAI Quant Ranking